NCT06445959View on ClinicalTrials.gov

Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions
Mutant IDH1 Inhibitor Olutasidenib
Interventions
DRUG

Olutasidenib

Given by PO

DRUG

Venetoclax

Given by PO

DRUG

Decitabine

Given by IV

DRUG

Decitabine/cedazuridine

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Rigel Pharmaceuticals,Inc.

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT06445959 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | Biotech Hunter | Biotech Hunter